Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Anaptysbio Inc
(NQ:
ANAB
)
25.04
+2.77 (+12.42%)
Streaming Delayed Price
Updated: 3:46 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Anaptysbio Inc
< Previous
1
2
3
4
Next >
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 06, 2023
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 06, 2023
Via
Benzinga
Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On Friday
January 06, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 500 points on Friday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround
September 19, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
January 06, 2023
Via
Benzinga
AnaptysBio Sells Royalty Interest In Cancer Drug For $45M
September 12, 2022
Via
Benzinga
Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback
September 02, 2022
Via
Benzinga
Short Volatility Alert: AnaptysBio, Inc.
May 26, 2022
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment...
Via
Benzinga
AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers
April 28, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 05, 2023
Via
Benzinga
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
January 05, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
December 02, 2022
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022
From
AnaptysBio, Inc.
Via
GlobeNewswire
Expert Ratings for AnaptysBio
November 09, 2022
Over the past 3 months, 4 analysts have published their opinion on AnaptysBio (NASDAQ:ANAB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
AnaptysBio to Participate in Upcoming November Investor Conferences
November 09, 2022
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
November 08, 2022
From
AnaptysBio, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial
October 05, 2022
Via
Benzinga
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
October 05, 2022
From
AnaptysBio, Inc.
Via
GlobeNewswire
This Analyst Slashes PT On Rent the Runway By Around 43%, Plus JP Morgan Predicts $84 For Oracle
September 13, 2022
Credit Suisse cut the price target for Rent the Runway, Inc. (NASDAQ: RENT) from $7 to $4. Rent the Runway shares fell 30.6% to trade at $3.42 on Tuesday.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022
September 13, 2022
Upgrades See all analyst ratings upgrades.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
September 01, 2022
Upgrades
Via
Benzinga
AnaptysBio Faces Another Setback For Imsidolimab, Stalls Work In Skin Scarring Indication
September 01, 2022
AnaptysBio Inc (NASDAQ: ANAB) announced topline data from its HARP Phase 2 trial of imsidolimab for moderate-to-severe hidradenitis suppurativa (HS).
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 01, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 31, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 07, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
May 27, 2022
During Friday's session, 59 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
June 02, 2022
During the Thursday's session, 100 stocks hit new 52-week lows.
Via
Benzinga
AnaptysBio's Return On Capital Employed Insights
May 24, 2022
Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting in a 11.42% decrease from last quarter.
Via
Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
April 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.